Results Healthcare advised Ajinomoto Bio-Pharma Services on the licencing of its Crystalomics Formulation Technology to Kyowa Kirin

  • Service: Licensing
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech
  • Engagement Type: Buy Side
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to

Sector Related Deals

Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has made an investment in
company name confidential
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has formed a strategic alliance with
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to
Jan 2021
has divested its Ringaskiddy analytics and testing site to
Oct 2020
has divested its Poznań, Poland manufacturing site to
Sep 2020
has divested its Barcelona manufacturing sites to
Sep 2020
has divested its Segré, France manufacturing facility to